|
|
|
|
LEADER |
01000cam a2200265 4500 |
001 |
619691042 |
003 |
DE-627 |
005 |
20240421013923.0 |
007 |
tu |
008 |
100224s2010 gw ||||| 00| ||eng c |
010 |
|
|
|a 2011377611
|
015 |
|
|
|a 10,N08
|2 dnb
|
015 |
|
|
|a 10,N08
|2 dnb
|
016 |
7 |
|
|a 015546340
|2 UK
|
016 |
7 |
|
|a 1000249891
|2 DE-101
|
020 |
|
|
|a 9783527318117
|c Pp. : EUR 159.00 (freier Pr.)
|9 978-3-527-31811-7
|
020 |
|
|
|a 3527318119
|c (hbk.) £140.00
|9 3-527-31811-9
|
024 |
3 |
|
|a 9783527318117
|
028 |
5 |
2 |
|a 1131811 000
|
035 |
|
|
|a (DE-627)619691042
|
035 |
|
|
|a (DE-576)329748688
|
035 |
|
|
|a (DE-599)DNB1000249891
|
035 |
|
|
|a (OCoLC)699557048
|
035 |
|
|
|a (OCoLC)699557048
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
044 |
|
|
|c XA-DE-BW
|
050 |
|
0 |
|a QP609.A86
|
060 |
|
0 |
|a W1
|
060 |
|
0 |
|a QU 136
|
082 |
0 |
|
|a 612.01516
|q LOC
|2 22
|
082 |
0 |
4 |
|a 610
|q DNB
|
084 |
|
|
|a WD 5200
|q hdub
|2 rvk
|0 (DE-625)rvk/148195:
|
084 |
|
|
|a 44.42
|2 bkl
|
090 |
|
|
|a a
|
245 |
1 |
0 |
|a Aspartic acid proteases as therapeutic targets
|c ed. by Arun K. Ghosh
|
264 |
|
1 |
|a Weinheim
|b Wiley-VCH
|c 2010
|
300 |
|
|
|a XXIII, 615 S.
|b Ill., graph. Darst.
|c 25 cm
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
490 |
1 |
|
|a Methods and principles in medicinal chemistry
|v 45
|
500 |
|
|
|a Literaturangaben
|
583 |
1 |
|
|a Archivierung/Langzeitarchivierung gewährleistet
|f PEBW
|x XA-DE-BW
|2 pdager
|5 DE-31
|
583 |
1 |
|
|a Archivierung prüfen
|c 20240324
|f DE-4165
|z 1
|2 pdager
|
650 |
|
0 |
|a Aspartic proteinases
|
650 |
|
0 |
|a Aspartic proteinases
|x Inhibitors
|x Therapeutic use
|
650 |
|
2 |
|a Aspartic Acid Proteases
|x therapeutic use
|
650 |
|
2 |
|a Aspartic Acid Proteases
|x antagonists & inhibitors
|
653 |
|
|
|a Aspartic proteinases
|
653 |
|
|
|a Aspartic proteinases
|a Inhibitors
|a Therapeutic use
|
655 |
|
7 |
|a Aufsatzsammlung
|0 (DE-588)4143413-4
|0 (DE-627)105605727
|0 (DE-576)209726091
|2 gnd-content
|
689 |
0 |
0 |
|D s
|0 (DE-588)4290183-2
|0 (DE-627)104256435
|0 (DE-576)210833459
|a Aspartatproteasen
|2 gnd
|
689 |
0 |
1 |
|D s
|0 (DE-588)4302415-4
|0 (DE-627)121603342
|0 (DE-576)211048763
|a Targeted drug delivery
|2 gnd
|
689 |
0 |
2 |
|D s
|0 (DE-588)4143176-5
|0 (DE-627)104408812
|0 (DE-576)209724234
|a Arzneimittelentwicklung
|2 gnd
|
689 |
0 |
|
|5 DE-101
|
689 |
1 |
0 |
|D s
|0 (DE-588)1028794711
|0 (DE-627)731606108
|0 (DE-576)376264608
|a Zielstruktur
|2 gnd
|
689 |
1 |
|
|5 (DE-627)
|
700 |
1 |
|
|a Ghosh, Arun K.
|e hrsg
|0 (DE-588)142231495
|0 (DE-627)634788590
|0 (DE-576)32962394X
|4 edt
|
830 |
|
0 |
|a Methods and principles in medicinal chemistry
|v 45
|9 4500
|w (DE-627)18394464X
|w (DE-576)036474312
|w (DE-600)1228220-0
|x 1432-4636
|7 ns
|
856 |
4 |
2 |
|u http://www.gbv.de/dms/bs/toc/619691042.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
856 |
4 |
2 |
|u http://deposit.d-nb.de/cgi-bin/dokserv?id=3428171&prov=M&dok_var=1&dok_ext=htm
|m X:MVB
|q text/html
|x Verlag
|3 Inhaltstext
|
856 |
4 |
2 |
|u https://swbplus.bsz-bw.de/bsz329748688cov.jpg
|m B:DE-576
|m X:wiley
|q application/pdf
|v 20110324000000
|x Verlag
|3 Cover
|
912 |
|
|
|a GBV_ILN_20
|
912 |
|
|
|a ISIL_DE-84
|
912 |
|
|
|a SYSFLAG_1
|
912 |
|
|
|a GBV_KXP
|
912 |
|
|
|a SSG-OLC-PHA
|
912 |
|
|
|a SSG-OPC-PHA
|
912 |
|
|
|a SSG-OPC-DE-84
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a ISIL_DE-28
|
912 |
|
|
|a GBV_ILN_69
|
912 |
|
|
|a ISIL_DE-9
|
912 |
|
|
|a GBV_ILN_2011
|
912 |
|
|
|a ISIL_DE-16
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a ISIL_DE-93
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a ISIL_DE-31
|
912 |
|
|
|a GBV_ILN_2141
|
912 |
|
|
|a ISIL_DE-16-300
|
935 |
|
|
|i sf
|
935 |
|
|
|i Blocktest
|
936 |
r |
v |
|a WD 5200
|b Aminosäuren und Amine
|k Biologie
|k Biophysik, Biochemie, Physiologische Chemie
|k Spezielle Biochemie und Biophysik
|k Biochemie und Biophysik organischer Verbindungen
|k Biologisch inaktive Proteine und Proteide insgesamt, auch: Proteinfaltung, Proteinbiosynthese
|k Aminosäuren und Amine
|0 (DE-627)1271489414
|0 (DE-625)rvk/148195:
|0 (DE-576)201489414
|
936 |
b |
k |
|a 44.42
|j Pharmazeutische Chemie
|0 (DE-627)18157179X
|
951 |
|
|
|a BO
|
953 |
|
|
|2 045F
|a 612.01516
|
980 |
|
|
|2 20
|1 01
|x 0084
|b 1179938968
|c 00
|f LS2
|d PM F 610 (45)
|e --%%--
|j --%%--
|c 09
|f --%%--
|d 2904-5800
|e --%%--
|j --%%--
|y k
|z 06-09-10
|
980 |
|
|
|2 62
|1 01
|x 0028
|b 1184752982
|c 00
|f 28/BB1
|d VS 5350 G427
|e u
|j --%%--
|h ACQ
|y zbb1
|z 30-09-10
|
980 |
|
|
|2 69
|1 01
|x 0009
|b 1182447953
|c 00
|f UB 660
|d 660/VS 5350 G427
|e u
|j --%%--
|y z
|z 15-11-10
|
980 |
|
|
|2 2011
|1 01
|x DE-16
|b 3108105213
|c 00
|f --%%--
|d UBN/WD 5200 G427
|e --%%--
|j --%%--
|y l01
|z 07-09-10
|
980 |
|
|
|2 2015
|1 01
|x DE-93
|b 3108105280
|c 00
|f --%%--
|d 6C 125
|e p
|j --%%--
|c 01
|f --%%--
|d LSV:Iz 750 M282
|e --%%--
|j --%%--
|k 1. Ex. im Lesesaal Vaihingen
|y l01
|z 08-09-10
|
980 |
|
|
|2 2018
|1 01
|x DE-31
|b 310810540X
|c 00
|f --%%--
|d 110 A 9439
|e --%%--
|j --%%--
|y l01
|z 05-10-10
|
980 |
|
|
|2 2141
|1 01
|x DE-16-300
|b 3108105469
|c 00
|f 261
|d P 8a
|e --%%--
|j --%%--
|c 01
|f --%%--
|d P 2
|e --%%--
|j --%%--
|c 02
|f --%%--
|d C 3d
|e --%%--
|j --%%--
|y l01
|z 26-11-18
|
983 |
|
|
|2 69
|1 00
|x DE-9
|8 00
|a VX 8560
|
983 |
|
|
|2 69
|1 00
|x DE-9
|8 01
|a VS 5350
|
984 |
|
|
|2 20
|1 01
|x 0084
|a 84$029045800
|
984 |
|
|
|2 62
|1 01
|x 0028
|a 28$011665211
|
984 |
|
|
|2 69
|1 01
|x 0009
|a 9$08629382
|
984 |
|
|
|2 2011
|1 01
|x DE-16
|a 103369113
|
984 |
|
|
|2 2018
|1 01
|x DE-31
|a 50215472031
|
984 |
|
|
|2 2141
|1 01
|x DE-16-300
|a 590665686
|
985 |
|
|
|2 62
|1 01
|x 0028
|a 2010.17290
|
985 |
|
|
|2 69
|1 01
|x 0009
|a 2010.13911
|
985 |
|
|
|2 2141
|1 01
|x DE-16-300
|a m/1800466
|
995 |
|
|
|2 62
|1 01
|x 0028
|a ACQ
|
998 |
|
|
|2 2015
|1 01
|x DE-93
|0 1009
|f 15
|